Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system

被引:152
作者
Szodoray, P
Alex, P
Brun, JG
Centola, M
Jonsson, R
机构
[1] Univ Bergen, Gade Inst, Broegelmann Res Lab, N-5021 Bergen, Norway
[2] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
[3] Univ Bergen, Haukeland Univ Hosp, Dept Rheumatol, Bergen, Norway
关键词
D O I
10.1111/j.0300-9475.2004.01432.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plasma cytokines play an important role in the pathogenesis of Sjogren's syndrome (SS) by initiating and perpetuating various cellular and humoural autoimmune processes. The aim of the present study was to describe a broad spectrum of T-cell and B-cell cytokines, growth factors, chemokines and molecules that could contribute to cell death in SS. A novel protein array system was utilized to measure simultaneously the levels of 25 plasma cytokines of patients with primary SS and healthy individuals. Furthermore, we correlated these plasma cytokine levels with potential laboratory and clinical parameters related to disease activity in SS. A subset of plasma cytokines [e.g. interleukin-1beta (IL-1beta), IL-6, CXCL8 (IL-8), IL-12 p40, IL-15, tumour necrosis factor-alpha (TNF-alpha), epidermal growth factor, CCL4 (MIP-1beta), CCL2 (MCP-1), CCL11 (Eotaxin), CCL5 (RANTES), TNF-RI and TNF-RII] was found to significantly differ between patients and controls. Also, distinct populations of cytokines were found to differentiate between patients with normal versus elevated ESR or IgG levels and patients with the presence or absence of extra-glandular manifestations (EGMs). Our results support the assumption that the multiplex cytokine array system can be successfully utilized in the diagnosis and disease management of SS. Furthermore, it may provide a powerful tool in the design of individualized anticytokine therapies.
引用
收藏
页码:592 / 599
页数:8
相关论文
共 17 条
  • [1] Chemokine and chemokine receptor expression determines the pattern of inflammatory cell infiltrates in Sjogren's syndrome
    Amft, N.
    Bowman, S. J.
    Curnow, J.
    Scheel-Toellner, D.
    Oates, J.
    Crocker, J.
    Hamburger, J.
    Mathews, J.
    Salmon, M.
    Buckley, C.
    [J]. RHEUMATOLOGY, 2001, 40 : 119 - 120
  • [2] Anaya JM, 2002, J RHEUMATOL, V29, P1874
  • [3] Collaborative research into outcome measures in Sjogren's syndrome - Update on disease assessment
    Bowman, SJ
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2002, 31 : 23 - 27
  • [4] García-Carrasco M, 2001, CLIN EXP RHEUMATOL, V19, P411
  • [5] Halse AK, 1999, SCAND J IMMUNOL, V49, P533
  • [6] Current issues in Sjogren's syndrome
    Jonsson, R
    Moen, K
    Vestrheim, D
    Szodoray, P
    [J]. ORAL DISEASES, 2002, 8 (03) : 130 - 140
  • [7] Jonsson R, 2001, SAMTERS IMMUNOLOGIC, P495
  • [8] Disproportion of helper T cell subsets in peripheral blood of patients with primary Sjogren's syndrome
    Kohriyama, K
    Katayama, Y
    [J]. AUTOIMMUNITY, 2000, 32 (01) : 67 - 72
  • [9] Differential immunological aberrations in patients with primary and secondary Sjogren's syndrome
    Kroneld, U
    Halse, AK
    Jonsson, R
    Bremell, T
    Tarkowski, A
    Carlsten, H
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1997, 45 (06) : 698 - 705
  • [10] Mustafa W, 1998, SCAND J IMMUNOL, V48, P623